Strong systems that enable trust and governance are key to enabling the growth of AI technologies in drug development.

TOKYO--(BUSINESS WIRE)--Rigaku Corporation, a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”), and SPERA PHARMA, Inc.

Dr. Maki brings nearly 20 years of biotechnology and pharma business development expertise as Company rapidly advances its powerful LNP platform to deliver mRNA-based therapies MENLO PARK, Calif. & ...

Asahi Kasei, a diversified global company, announced the successful completion of its acquisition of Aicuris Anti-infective ...

At Bayer, a groupwide restructuring is being rolled out as a top priority. But, to Juergen Eckhardt, M.D., who leads both the investment arm Leaps by Bayer and the pharma business development team, ...

In 2022, the combined research and development (R&D) expenditure of the U.S. pharmaceutical industry consisted of more than $100 billion. While this is a significantly expansive market, approximately ...

Macomics continues to expand its leadership team to accelerate the development of first-in-class macrophage-targeted therapies Simon Dew brings over 25 years of experience in pharmaceutical business ...

Dynamic Vapor Sorption (DVS) is a potent analytical technique used in the pharmaceutical industry to determine how much vapor a sample absorbs or desorbed under regulated temperature and humidity ...

Forbes contributors publish independent expert analyses and insights. I write about business model strategy and execution across healthcare. Jun 02, 2025, 10:17am EDT Trucks drive in front of Teva ...

Hengrui Pharma reported steady growth in the first quarter of 2026. In Q1 2026, the Company recorded revenue of RMB 8.14 billion, up 12.98% year-over-year, while net profit attributable to ...